Loading...
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
24 Jan 26
Views
11
24 Jan
CHF 38.45
AnalystConsensusTarget's Fair Value
CHF 36.14
6.4% overvalued intrinsic discount1Y
107.8%7D
1.6%1Y
107.8%7D
1.6%You can edit this narrative until Jan 25 8:05 AM. Then, changes will post as Updates.
Author's Valuation
CHF 36.146.4% overvalued intrinsic discount
AnalystConsensusTarget Fair Value